According to Steven P. Treon, MD, PhD, mutations in MYD88 and CXCR4 can effectively be used to tailor treatment for patients with Waldenström’s macroglobulinemia (WM).
“Linking biological data to clinical data is beginning to identify clinically distinct… Continue reading
Article from the New England Journal of Medicine
Many of you have had questions about the pathway that led to the FDA approval of Imbruvica for WM. I wanted to share with you the attached video of Dr Treon’s interview on this historic approval which I hope… Continue reading
Featuring information on:
In the attached report which was just published online in the journal BLOOD, we show how these mutations impact disease presentation and overall survival in WM. CXCR4 is a gene that makes a protein that directs cells to the… Continue reading